Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, 2025. Despite a significant drop in net profit, revenue and EBITDA have grown. Increased biosimilar market share and strategic approvals are expected to drive future growth.
Holi-to-Holi multibaggers: From market favourites to hidden gems, 80 stocks deliver up to 1,822% returns
Ahead of Holi 2026, several Indian stocks have emerged as multibaggers since last Holi, delivering exceptional returns despite market volatility. While strong performers span sectors